Contribution of the Interferon score in the management of an anti-NXP2 dermatomyositis patient with calcinosis successfully treated with tofacitinib.

Marie Robert,Laure Gallay,Lorna Garnier,Rémi Pescarmona,Arnaud Hot

Joint bone spine（2023）

引用 1|浏览6

暂无评分

摘要

• The IFN score can drive the use of tofacitinib in dermatomyositis (DM). • Tofacitinib should be considered for DM patients with refractory calcinosis . • Prolonged treatment with tofacitinib is required to allow regression of calcinosis.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要